Trinity Biotech Announces Quarter 3 Financial Results

Profit After Tax increases by 13% to $4.5m

EPS increases by 12% to 20.7 cents per ADR

DUBLIN, Ireland, Oct. 18, 2012 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2012.

Quarter 3 Results

Total revenues for Q3, 2012 were $20.9m which compares to $19.8m in Q3, 2011, representing an increase of 5.2%. However, taking in to account foreign exchange movements, the increase for the quarter is approximately 8%.

Point-of-Care revenues for Q3, 2012 increased by over 20% to $4.8m when compared to Q3, 2011 due to continued strong HIV sales in East Africa.

Clinical Laboratory revenues increased from $15.9m to $16.1m, which represents an increase of 1.4% versus Q3, 2011. Excluding the impact of foreign exchange movements (weaker Euro) and a decrease in Fitzgerald revenues the underlying increase was 6%.

Revenues for Q3, 2012 by key product area were as follows:

Quarter 3
Quarter 3
US$'000 US$'000 %
Point-of-Care 3,941 4,751 20.6%
Clinical Laboratory 15,885 16,100 1.4%
Total 19,826 20,851 5.2%

Gross profit for Q3, 2012 amounted to $10.6m which represents a gross margin of 51%, which is a slight decrease on the 51.7% in the corresponding period last year. This decrease is attributable to the impact of increased instrument sales, particularly to sales of our state-of-the-art Diabetes analyzer, Premier.

Research and Development expenses were $0.8m thus representing a similar level to the corresponding period last year. Similarly, Selling, General and Administrative (SG&A) expenses have also remained broadly constant at $5.1m.

Operating profit for the quarter was over $4.3m, compared to $4.1m in Q3, 2011. Operating margins have now reached 20.9% which is a new high for the company and compares favourably to the 20.7% reported in Q3, 2011.

Meanwhile, the tax charge this quarter was $0.5m which represents an effective tax rate of 9.3% and again this compares favourably with 15.3% in the comparable quarter.

Profit After Tax has increased to $4.5m from $3.9m which is an increase of 13.3% over Q3, 2011. Meanwhile, EPS for the quarter increased by 11.9% from 18.5 cents to 20.7 cents.

Free Cash Flows generated during the quarter were $1.9m. This in turn was offset by share repurchases of $1.1m, resulting in an increase in cash for the quarter of $0.8m to $74.5m

Recent Developments


During the quarter, the Company shipped 54 of our new Premier instruments compared to 52 instruments in Q2, 2012. The level of sales was in line with expectations and reflects the slower summer period particularly in continental Europe. Previous growth rates are expected to resume in Q4, 2012 with the result that we are confident of meeting our target of 200 instruments for the year. As in previous quarters, sales were made in a wide range of jurisdictions including, the USA, Europe, South America, South-east Asia, Turkey and, for the first time, the important market of Taiwan.

Fiomi Update

It is now just over six months since we acquired Fiomi Diagnostics, in Uppsala, Sweden. During that period we have recruited a number of key individuals to complete the development of a Troponin I, point-of-care cardiac test and associated instrument. We are very pleased with the progress being made to date. Already, our current assay demonstrates significantly better performance than each of the leading point-of-care products on the market. Over the coming months we will be incorporating further enhancements which we are confident will result in this test meeting the FDA's new guidelines for measuring Troponin I – thus making it by far the most accurate test in the point-of-care cardiac market. Given the strong progress being made with Troponin I, we have now commenced the development of our next test on the Fiomi platform, BNP, the worldwide indicator of heart failure. We remain on target to launch a Troponin I product during 2013 and with its BNP equivalent to follow in 2014.

Share buyback

During the quarter, we repurchased 85,000 ADRs at an average price of $12.53 as part of our share buyback program. The total amount spent on repurchases during the quarter was approximately $1.1m. This brings the total spent since the program began to over $10m.

B Shares

In September, the Company held an extraordinary general meeting (EGM) which approved the conversion of all of the B shares in the Company into A shares at an effective discount of 15%. This discount will result in an improvement in annual EPS of approximately 0.25%.


Commenting on the results, Kevin Tansley, Chief Financial Officer, said, "Profits this quarter increased by 13% to $4.5m, whilst EPS grew by 12% to 20.7 cents per share. This was achieved through a combination of revenue growth and improved operating margins. This quarter's operating margins reached 20.9%, which is the highest in the Company's history. This will be of critical importance going forward as we seek to leverage future revenue growth and thus further increase profitability."

Ronan O'Caoimh, CEO, stated, "Coupled with achieving record profits we are also very active in developing growth opportunities on a number of fronts. Sales of Premier continue to meet expectations despite the traditional summer slowdown in Europe, with sales expected to grow significantly in Quarter 4. We are thus comfortable that we will achieve our target of 200 instruments for the year as a whole, making it a very successful first full year post launch. We are also making excellent progress in developing our new point-of-care Troponin I cardiac test. Based on recent internal studies we are confident that the test will meet the new FDA Troponin I guidelines. We expect to launch the product in Europe in 2013, with FDA approval to follow in 2014. Other areas of focus for us include the launch of our new range of point-of-care tests and FDA approval of our new Vitamin D test, which is now imminent."

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website:

The Trinity Biotech plc logo is available at

Trinity Biotech plc
Consolidated Income Statements
(US$000's except share data) Three Months Ended
Sept 30, 2012
Three Months Ended
Sept 30, 2011
Nine Months Ended
Sept 30, 2012
Nine Months Ended
Sept 30, 2011
(unaudited) (unaudited) (unaudited) (unaudited)
Revenues 20,851 19,826 61,686 57,935
Cost of sales (10,213) (9,571) (29,967) (28,119)
Gross profit 10,638 10,255 31,719 29,816
Gross profit % 51.0% 51.7% 51.4% 51.5%
Other operating income 86 191 375 721
Research & development expenses (767) (857) (2,365) (2,344)
Selling, general and administrative expenses (5,147) (5,237) (15,591) (15,500)
Indirect share based payments (461) (252) (1,361) (1,006)
Operating profit 4,349 4,100 12,777 11,687
Financial income 597 549 1,748 1,822
Financial expenses (26) (3) (62) (10)
Net financial income 571 546 1,686 1,812
Profit before tax 4,920 4,646 14,463 13,499
Income tax expense (460) (711) (1,591) (1,950)
Profit for the period 4,460 3,935 12,872 11,549
Earnings per ADR (US cents) 20.7 18.5 60.2 54.1
Diluted earnings per ADR (US cents) 19.8 17.7 57.5 51.8
Weighted average no. of ADRs used in computing basic earnings per ADR 21,513,896 21,297,539 21,399,295 21,345,527
Weighted average no. of ADRs used in computing diluted earnings per ADR 22,488,295 22,268,461 22,382,750 22,284,561
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
Trinity Biotech plc
Consolidated Balance Sheets
Sept 30,
June 30,
March 31,
Dec 31,
US$ '000 US$ '000 US$ '000 US$ '000
(unaudited) (unaudited) (unaudited) (audited)
Non-current assets
Property, plant and equipment 8,618 8,242 7,823 7,626
Goodwill and intangible assets 65,644 62,276 59,832 45,390
Deferred tax assets 3,106 2,986 3,034 2,977
Other assets 786 836 528 493
Total non-current assets 78,154 74,340 71,217 56,486
Current assets
Inventories 21,427 20,794 19,301 19,838
Trade and other receivables 15,569 14,924 25,677 23,973
Income tax receivable 302 290 271 117
Cash and cash equivalents 74,455 73,605 65,499 71,085
Total current assets 111,753 109,613 110,748 115,013
TOTAL ASSETS 189,907 183,953 181,965 171,499
Equity attributable to the equity holders of the parent
Share capital 1,125 1,117 1,109 1,106
Share premium 4,819 3,740 3,086 2,736
Accumulated surplus 155,102 150,984 151,082 143,482
Other reserves 4,011 3,837 4,021 4,008
Total equity 165,057 159,678 159,298 151,332
Current liabilities
Interest-bearing loans and borrowings -- 30 70 108
Income tax payable 2,061 1,704 1,879 1,582
Trade and other payables 11,795 11,766 10,104 11,589
Provisions 50 50 50 50
Total current liabilities 13,906 13,550 12,103 13,329
Non-current liabilities
Other payables 3,291 3,269 3,273 10
Deferred tax liabilities 7,653 7,456 7,291 6,828
Total non-current liabilities 10,944 10,725 10,564 6,838
TOTAL LIABILITIES 24,850 24,275 22,667 20,167
TOTAL EQUITY AND LIABILITIES 189,907 183,953 181,965 171,499
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
Trinity Biotech plc
Consolidated Statement of Cash Flows
(US$000's) Three Months Ended
Sept 30, 2012
Three Months Ended
Sept 30, 2011
Nine Months Ended
Sept 30, 2012
Nine Months Ended
Sept 30, 2011
(unaudited) (unaudited) (unaudited) (unaudited)
Cash and cash equivalents at beginning of period 73,605 71,422 71,085 58,002
Operating cash flows before changes in working capital 5,587 5,029 16,312 14,967
Changes in working capital (695) (335) (3,286) (231)
Cash generated from operations 4,892 4,694 13,026 14,736
Net Interest and Income taxes received 554 417 1,055 1,463
Capital Expenditure & Financing (net) (3,527) (2,069) (8,684) (6,268)
Free cash flow 1,919 3,042 5,397 9,931
Proceeds from sale of Coagulation product line -- -- 11,250 11,250
Cash paid to acquire Phoenix Bio-tech -- (333) (333) (1,833)
Cash paid to acquire Fiomi Diagnostics -- -- (5,624) --
Dividend Payment -- -- (3,223) (2,149)
Repurchase of own company shares (1,069) (3,003) (4,097) (4,073)
Cash and cash equivalents at end of period 74,455 71,128 74,455 71,128
The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).
CONTACT: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700

Source:Trinity Biotech plc